Pain outcomes in patients with advanced breast cancer and bone metastases

Charles S. Cleeland(The University of Texas MD Anderson Cancer Center), Karen Chung(Amgen (United States)), Roger von Moos(Kantonsspital Graubünden), Mark Clemons(University of Ottawa), Stefania Salvagni(Ospedale di Parma), Roger Dansey(Memorial Sloan Kettering Cancer Center), Qi Jiang(National Cancer Centre Japan), Jean‐Jacques Body(Université Libre de Bruxelles), Donald L. Patrick(University of Washington), Susan D. Mathias(Health Outcomes Solutions (United States)), Norikazu Masuda(Osaka National Hospital), Lesley Fallowfield(Brighton and Sussex Medical School), Richard de Boer(Western Hospital), Yi Qian(Amgen (United States)), Célia Tosello Oliveira(Instituto Brasileiro de Controle do Câncer), Ada Braun(Amgen (United States)), Katia Tonkin(National Cancer Centre Japan), Allan Lipton(American Society of Clinical Oncology), Alison Stopeck(National Cancer Centre Japan)
Cancer
September 5, 2012
10.1002/cncr.27789
Cited by 155

Related Papers

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k